01
Cash & equivalents decreased 63.1%
Cash & equivalents changed -63.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$20.5M→$7.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTLite Strategy, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -63.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Net income changed -820.9% from the comparable as-filed period.
Operating income changed -679.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LITS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-325026SEC ↗8-KJul 24, 2026Period Jul 24, 20260001193125-26-316284SEC ↗4Jun 25, 2026Period Jun 24, 20260001193125-26-282864SEC ↗8-KMay 13, 2026Period May 13, 20260001193125-26-220697SEC ↗10-QMay 13, 2026Period Mar 31, 20260001193125-26-220687SEC ↗8-KFeb 17, 2026Period Feb 17, 20260001193125-26-053243SEC ↗10-QFeb 17, 2026Period Dec 31, 20250001193125-26-053215SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 24, 2026Filed Jun 25, 2026 | Flynn James PDirector | Open Market PurchaseDirect | 25,000 | $1 | $21,388 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -91.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-03-31. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-049089